Barakat Pharmaceutical Group
Barakat Pharmaceutical Group Public Joint Stock Company is a Tehran-based listed Iranian pharmaceutical and healthcare holding company. Its portfolio spans medicine manufacturing, biotechnology, oncology, cell and regenerative therapies, and pharmaceutical distribution, with activities linked to Tehran, Kordan and Rasht. The group is a relevant entry point for assessing Iran’s pharmaceutical manufacturing and healthcare investment landscape.
Operations & footprint
Products and services
Barakat Pharmaceutical Group operates a diversified pharmaceutical and healthcare holding with investments and subsidiaries across generic medicines, specialty pharmaceuticals, oncology medicines, biotechnology, recombinant products, cell and regenerative therapies, pharmaceutical distribution, APIs and raw materials, medical and healthcare products, research and development, pharmaceutical investment, and health-sector infrastructure. Subsidiaries and portfolio companies include businesses such as Alborz Darou, Sobhan Darou, Sobhan Oncology, Iran Darou, CellTech Pharmed, Shifa Pharmed, Samen-related pharmaceutical operations, and pharmaceutical distribution activities.
Operations and assets
The group operates through portfolio companies and investments covering drug production, biotechnology, oncology medicines, cell and regenerative therapies, pharmaceutical distribution and healthcare-related development activities.
Geographic footprint
Iran, with activities associated with Tehran, Kordan in Alborz Province, and Rasht.
Ownership & group structure
Subsidiaries and group companies
The group’s portfolio includes pharmaceutical manufacturing, biotechnology, oncology, cell-therapy and distribution businesses. Named portfolio companies include Alborz Darou, Sobhan Darou, Sobhan Oncology, Iran Darou, CellTech Pharmed and Shifa Pharmed.
Commercial and investment relevance
Barakat Pharmaceutical Group is relevant for investors assessing listed pharmaceutical-holding exposure, generic and specialty medicines, biotech, oncology, regenerative medicine, domestic drug localization, pharmaceutical distribution, and Iran's healthcare investment ecosystem. It can support analysis of regulated drug pricing, portfolio-company performance, import substitution, R&;D capability, medicine shortages, healthcare demand, and sector consolidation. Due diligence should review updated Codal disclosures, TSE trading status, current holding structure, subsidiary ownership percentages, relationship with Barkat Foundation and EIKO-linked structures, sanctions-screening considerations, portfolio-company profitability, intercompany transactions, drug pricing, government receivables, product registrations, export activity, R&;D pipeline, financing, and exposure to imported APIs and specialized equipment. Barakat connects manufacturers, biotechnology ventures and distribution channels within Iran’s pharmaceutical supply chain. It is relevant to suppliers of active ingredients, production equipment and specialised healthcare inputs, as well as partners seeking access to a multi-company pharmaceutical portfolio.
Constraints, risk & compliance
Key risks and constraints
Portfolio performance is exposed to regulated pharmaceutical pricing, the availability of imported active ingredients and specialised equipment, and execution across manufacturing, biotechnology and distribution businesses.
Sanctions and compliance considerations
Cross-border procurement of pharmaceutical inputs, specialised equipment and technology requires transaction-specific sanctions and export-control screening.
Need more than a public profile?
Ask Hormuz to investigate, verify or act locally around Barakat Pharmaceutical Group. Tell us exactly what you need.
Connected Intelligence
Relevant geography, industry, market and execution context for this profile.
Frequently asked questions
Direct answers to the questions most likely to arise when reviewing this profile.
What does Barakat Pharmaceutical Group do?
Barakat Pharmaceutical Group is a listed pharmaceutical and healthcare holding company with interests in drug manufacturing, biotechnology, oncology, cell and regenerative therapies, and pharmaceutical distribution.
Where does Barakat Pharmaceutical Group operate?
The group operates in Iran, with activities associated with Tehran, Kordan in Alborz Province and Rasht.
Is Barakat Pharmaceutical Group publicly listed?
Yes. Barakat Pharmaceutical Group Public Joint Stock Company is listed on the Tehran Stock Exchange under the ticker برکت.
Why is Barakat Pharmaceutical Group commercially relevant?
Its multi-company portfolio links pharmaceutical manufacturing, biotechnology and distribution, making it relevant to healthcare-sector suppliers, commercial partners and investors assessing Iran’s drug industry.